Table 4.
Comparison of the predicted and experimentally tested effects of mutations on the aggregation propensity of amyloidogenic proteins.
| Sequence Name | ΔNa4vSSa | Experimentalb | References |
| Peptide Aβ42 A21G | -16 | - | [84] |
| Peptide Aβ42 E22K | 15 | + | [84] |
| Peptide Aβ42 E22G | 29 | + | [84] |
| Peptide Aβ42 E22Q | 5 | + | [84] |
| Peptide Aβ42 F19P | -68 | - | [85] |
| Peptide Aβ42 F19T | -63 | - | [35] |
| Peptide Aβ42 D23N | 16 | + | [86] |
| Peptide Aβ42 F19D | -118 | - | [12] |
| Peptide Aβ42 I31L | -15 | - | [87] |
| Peptide Aβ42 I32L | -15 | - | [87] |
| Peptide Aβ42 I41G | -62 | - | [87] |
| Peptide Aβ42 I41A | -49 | - | [87] |
| Peptide Aβ42 I41L | -12 | - | [87] |
| Peptide Aβ42 A42G | -10 | - | [87] |
| Peptide Aβ42 A42V | 32 | + | [87] |
| Peptide Aβ42 Δ 1–4 | 59 | + | [88] |
| Peptide Aβ42 Δ 1–9 | 237 | + | [88] |
| Peptide Aβ42 Δ 40–42 | -63 | - | [88] |
| Peptide AβgΔ 41–42 | -34 | - | [36] |
| Peptide Aβg5 | 89 | + | [36] |
| Peptide Aβg6 | 111 | + | [36] |
| Peptide Aβg7 | 167 | + | [36] |
| Peptide Aβ42 V12E+V18E+M35T+I41N | -312 | - | [87] |
| Peptide Aβ42 F19S+L34P | -123 | - | [87] |
| TAU R5L | 2 | + | [89] |
| TAU R406W | 2 | + | [90] |
| TAU G272V | 2 | + | [90] |
| TAU Y310W | 0 | = | [39] |
| TAU P301L | 1 | + | [40] |
| TAU S320F | 2 | + | [91] |
| α-synucleinA30P | -1 | = | [92] |
| α-synucleinE46K | 2 | + | [92] |
| α-synucleinA53T | -1 | + | [92] |
| α-synucleinA76E | -5 | - | [93] |
| α-synucleinA76R | -3 | - | [93] |
| Amylin (Rat) R18H | 9 | + | [94] |
| Amylin (Rat) L23F | 17 | + | [94] |
| Amylin (Rat) V26I | 11 | + | [94] |
| Amylin (Rat) R18H+L23F+V26I | 34 | + | [94] |
| Amylin (human) (22–27) N22A | 21 | + | [68] |
| Amylin (human) (22–27) F23A | -59 | - | [68] |
| Amylin (human) (22–27)G24A | 16 | + | [68] |
| Amylin (human) (22–27) I26A | -61 | - | [68] |
| Amylin (human) (22–27) L27A | -23 | - | [68] |
| Amylin (human) S20G | -106 | + | [95] |
| Amylin (human) ProIAPP | -90 | +? | [96] |
| Human PrP H111A | 5 | +/= | [97] |
| Human PrP H111K | 0 | -/= | [97] |
| Human PrP A117V | 7 | + | [97] |
| Human PrP V210I | 1 | + | [98] |
| Stefin R68X | 37 | + | [41] |
| Stefin G4R | -6 | - | [41] |
| SH3 n47a | 17 | + | [46] |
aRelative change in Na4vSS upon mutation, expressed as percentage.
ΔNa4vSS = ((Na4vSSmut - Na4vSSwt)/|Na4vSSwt|)*100
Na4vSSmut refers to the Na4vSS value of the mutant sequence.
Na4vSSwt refers to the Na4vSS value of the wild type sequence.
bChanges in aggregation determined experimentally.
Symbols: + increase; - decrease; = no significant change.